FibroGen

FibroGen is a research-based biotechnology company that leverages its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapies for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative drugs for the treatment of anemia, fibrotic diseases, and cancer. FibroGen's product Roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, is in global Phase 3 clinical development for the treatment of anemia associated with chronic kidney disease (CKD) and is currently under review by China's National Medical Products Administration (NMPA, formerly CFDA) for a New Drug Application.